Addition of ribociclib to firstline letrozole improves outcomes and maintains quality of life in postmenopausal women with HR+, HER2– advanced breast cancer, regardless of visceral metastases or dose intensity: Subgroup analyses from the MONALEESA-2 trial
Standard initial treatment for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer is endocrine therapy (ET).1 Current guidelines support the use of ET as monotherapy or...